Rosa Lapalombella

Has grant

Ohio State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Understanding Richter's Transformation in the targeted therapies era

Open Date: 2020-09-11

Close Date: 2025-05-31

Grant: Close

Targeting NAMPT in Acute Myeloid Leukemia

Open Date: 2018-08-02

Close Date: 2025-07-31

Grant: Close

Targeted Therapies for Richters Transformation

Open Date: 2017-02-07

Close Date: 2022-01-31

Grant: Close

Pathogenesis and Treatment of Richter’s Transformation

Open Date: 2017-01-01

Close Date: 2020-12-31

Grant: Close

Dual targeting of XPO1 and BTK in B cell malignancies

Open Date: 2015-04-21

Close Date: 2021-03-31

Articles (28)

Year:

2026

Year:

2026

Year:

2026

Inhibition of the tyrosine kinase BTK is a major therapeutic strategy for treating B-cell malignancies, including chronic lymphocytic leukemia (CLL). However, resistance can emerge when tumor cells acquire mutations that abrogate drug binding or when BTK activates B-cell receptor (BCR) signaling by mechanisms independent of its kinase activity. In this study, we identified upregulation of PKCβ in samples from patients with CLL resistant to BTK inhibitors (BTKi) and characterized the PKCβ inhibitor MS-553. MS-553 reduced BCR and Wnt/β-catenin signaling, overcame stromal cell mediated protection, and synergized with venetoclax in CLL samples. MS-553 also retained the cytotoxicity and inhibition of both BCR and Wnt/β-catenin signaling in models (cell lines and primary samples) of covalent BTKi-resistant (C481S BTK ) and noncovalent BTKi-resistant (T474I or L528W BTK ) CLL. Furthermore, MS-553 delayed disease progression and prolonged survival in the Eμ-MTCP1 murine model of CLL. Collectively our results demonstrate that selective inhibition of PKCβ has the potential to overcome BTKi-resistant CLL. Significance: This study identified and characterized PKCβ as a therapeutic target in CLL, including CLL resistant to BTKis. Inhibition of PKCβ suppressed both BCR and Wnt/β-catenin signaling, delayed disease progression in vivo , overcame BTKi resistance mechanisms, and enhanced response to BCL-2 inhibition. See related commentary by Jebaraj and Stilgenbauer, p. 21

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (28)

Alice Mims

Ohio State University

UNITED STATES
View details

Cem Meydan

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Marlise Luskin

Dana-Farber Cancer Institute

UNITED STATES
View details

Girish Venkataraman

Asst Professor

University of Chicago Pritzker School of Medicine

UNITED STATES
View details

Walter Hanel

Ohio State University

UNITED STATES
View details

Robert Baiocchi

-

UNITED STATES
View details

Sandeep Gurbuxani

Professor

University of Chicago

UNITED STATES
View details

Anand Ashwin Patel

Assistant Professor of Medicine

-

UNITED STATES
View details

Adam Sperling

Assistant Professor

Stanford University

UNITED STATES
View details

Benjamin Ebert

Dana-Farber Cancer Institute

UNITED STATES
View details

Lapo Alinari

Ohio State University

UNITED STATES
View details

Lachelle Dawn Weeks

Dana-Farber Cancer Institute

UNITED STATES
View details

chunhua song

Associate Professor

Ohio State University

UNITED STATES
View details

Satishkumar Singh

Ohio State University

UNITED STATES
View details

Samir Parekh

Director, Center of Excellence for Multiple Myeloma

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Daniel Arber

Professor and Chair

University of Chicago

UNITED STATES
View details

Ulrich Steidl

Albert Einstein College of Medicine

UNITED STATES
View details

Lucy A. Godley

Northwestern Medicine

UNITED STATES
View details

Wing Keung Chan

Assistant Professor

Ohio State University

UNITED STATES
View details

Peng Wang

Associate professor

University of Chicago Medicine

UNITED STATES
View details

Robert Faryabi

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Wendy Stock

Professor of Medicine

University of Chicago

UNITED STATES
View details

John Greally

Director, New York Center for Rare Diseases (NYCRD)

Albert Einstein College of Medicine

UNITED STATES
View details

Richard Larson

Professor

University of Chicago

UNITED STATES
View details

Angela Lager

Assistant Professor

University of Chicago

UNITED STATES
View details

Lalit Sehgal

Associate Professor

Ohio State University

UNITED STATES
View details

Violetta Leshchenko

Senior Scientist

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Christopher Mason

Professor

Weill Cornell Medical College

UNITED STATES
View details